Loading…
Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis
The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temper...
Saved in:
Published in: | Journal of controlled release 2013-10, Vol.171 (2), p.143-151 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843 |
---|---|
cites | cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843 |
container_end_page | 151 |
container_issue | 2 |
container_start_page | 143 |
container_title | Journal of controlled release |
container_volume | 171 |
creator | Jung, Young-Seok Park, Wooram Na, Kun |
description | The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems.
Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted] |
doi_str_mv | 10.1016/j.jconrel.2013.07.012 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500772821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913004069</els_id><sourcerecordid>1500772821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxiMEotvCIwA-cknwv8TJCaEKKFIlDrRny7EnXa8cO9jOqn0E3hpHu3DtaTSj38z32V9VvSO4IZh0nw7NQQcfwTUUE9Zg0WBCX1Q70gtW82FoX1a7wvU169rhorpM6YAxbhkXr6sLyvoec0F21Z87mBeIKq8R6jmY1akMBvngdTgqBz4j63MBdLbBoyKZY3BOjQ5KMy8OHtEUIsp7QC74h7qwMzLg7BHiEwoTgqw8RA1LRjmgHEFlFPewzioHa5CKeR9ttulN9WpSLsHbc72q7r99vbu-qW9_fv9x_eW21pzSXI8tG8eOjlqIVuCRYo6nllA6DUYwQ_SExTZsR26mQQAD1m-F884YUD1nV9XH090lht8rpCxnmzSUN3kIa5KkxVgI2lPyPMoZ6chA26Gg7QnVMaQUYZJLtLOKT5JguQUmD_IcmNwCk1jIEljZe3-WWMcZzP-tfwkV4MMJmFSQ6iHaJO9_lQvFJSk22Sb9-URA-bWjhSiTtuA1GBtBZ2mCfcbEX_nrtlk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1431619259</pqid></control><display><type>article</type><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Jung, Young-Seok ; Park, Wooram ; Na, Kun</creator><creatorcontrib>Jung, Young-Seok ; Park, Wooram ; Na, Kun</creatorcontrib><description>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems.
Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.07.012</identifier><identifier>PMID: 23880471</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>active sites ; animal models ; Animals ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - chemistry ; Antirheumatic Agents - pharmacokinetics ; Arthritis, Experimental ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Bioavailability ; blood serum ; Cell Line, Tumor ; composite polymers ; Drug delivery ; Drug Delivery Systems ; electrolytes ; Electrostatic interactions ; Etanercept ; Female ; Glucans - chemistry ; hydrophobic bonding ; hydrophobicity ; Immunoglobulin G - administration & dosage ; Immunoglobulin G - chemistry ; in vitro studies ; Mice ; mixing ; Noncovalent interactions ; pharmacokinetics ; Polyesters - chemistry ; Rats ; Rats, Inbred Lew ; Receptors, Tumor Necrosis Factor - administration & dosage ; Receptors, Tumor Necrosis Factor - chemistry ; Rheumatoid arthritis ; Temperature ; therapeutics ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Journal of controlled release, 2013-10, Vol.171 (2), p.143-151</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</citedby><cites>FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23880471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jung, Young-Seok</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Na, Kun</creatorcontrib><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems.
Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</description><subject>active sites</subject><subject>animal models</subject><subject>Animals</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - chemistry</subject><subject>Antirheumatic Agents - pharmacokinetics</subject><subject>Arthritis, Experimental</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Bioavailability</subject><subject>blood serum</subject><subject>Cell Line, Tumor</subject><subject>composite polymers</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>electrolytes</subject><subject>Electrostatic interactions</subject><subject>Etanercept</subject><subject>Female</subject><subject>Glucans - chemistry</subject><subject>hydrophobic bonding</subject><subject>hydrophobicity</subject><subject>Immunoglobulin G - administration & dosage</subject><subject>Immunoglobulin G - chemistry</subject><subject>in vitro studies</subject><subject>Mice</subject><subject>mixing</subject><subject>Noncovalent interactions</subject><subject>pharmacokinetics</subject><subject>Polyesters - chemistry</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Receptors, Tumor Necrosis Factor - administration & dosage</subject><subject>Receptors, Tumor Necrosis Factor - chemistry</subject><subject>Rheumatoid arthritis</subject><subject>Temperature</subject><subject>therapeutics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxiMEotvCIwA-cknwv8TJCaEKKFIlDrRny7EnXa8cO9jOqn0E3hpHu3DtaTSj38z32V9VvSO4IZh0nw7NQQcfwTUUE9Zg0WBCX1Q70gtW82FoX1a7wvU169rhorpM6YAxbhkXr6sLyvoec0F21Z87mBeIKq8R6jmY1akMBvngdTgqBz4j63MBdLbBoyKZY3BOjQ5KMy8OHtEUIsp7QC74h7qwMzLg7BHiEwoTgqw8RA1LRjmgHEFlFPewzioHa5CKeR9ttulN9WpSLsHbc72q7r99vbu-qW9_fv9x_eW21pzSXI8tG8eOjlqIVuCRYo6nllA6DUYwQ_SExTZsR26mQQAD1m-F884YUD1nV9XH090lht8rpCxnmzSUN3kIa5KkxVgI2lPyPMoZ6chA26Gg7QnVMaQUYZJLtLOKT5JguQUmD_IcmNwCk1jIEljZe3-WWMcZzP-tfwkV4MMJmFSQ6iHaJO9_lQvFJSk22Sb9-URA-bWjhSiTtuA1GBtBZ2mCfcbEX_nrtlk</recordid><startdate>20131028</startdate><enddate>20131028</enddate><creator>Jung, Young-Seok</creator><creator>Park, Wooram</creator><creator>Na, Kun</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20131028</creationdate><title>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</title><author>Jung, Young-Seok ; Park, Wooram ; Na, Kun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>active sites</topic><topic>animal models</topic><topic>Animals</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - chemistry</topic><topic>Antirheumatic Agents - pharmacokinetics</topic><topic>Arthritis, Experimental</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Bioavailability</topic><topic>blood serum</topic><topic>Cell Line, Tumor</topic><topic>composite polymers</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>electrolytes</topic><topic>Electrostatic interactions</topic><topic>Etanercept</topic><topic>Female</topic><topic>Glucans - chemistry</topic><topic>hydrophobic bonding</topic><topic>hydrophobicity</topic><topic>Immunoglobulin G - administration & dosage</topic><topic>Immunoglobulin G - chemistry</topic><topic>in vitro studies</topic><topic>Mice</topic><topic>mixing</topic><topic>Noncovalent interactions</topic><topic>pharmacokinetics</topic><topic>Polyesters - chemistry</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Receptors, Tumor Necrosis Factor - administration & dosage</topic><topic>Receptors, Tumor Necrosis Factor - chemistry</topic><topic>Rheumatoid arthritis</topic><topic>Temperature</topic><topic>therapeutics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jung, Young-Seok</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Na, Kun</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jung, Young-Seok</au><au>Park, Wooram</au><au>Na, Kun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-10-28</date><risdate>2013</risdate><volume>171</volume><issue>2</issue><spage>143</spage><epage>151</epage><pages>143-151</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>The clinical applications of etanercept (Enbrel), an emerging therapeutic protein for rheumatoid arthritis (RA), are limited by its instability and low bioavailability. In this study, a long-term and efficient therapeutic nanocomplex formulation for RA treatment was developed in the form of a temperature-modulated noncovalent interaction controllable (TMN) complex based on a temperature-sensitive amphiphilic polyelectrolyte (succinylated pullulan-g-oligo(l-lactide); SPL). The TMN complexes were prepared by simply mixing the negatively charged SPL copolymer and the positively charged etanercept via electrostatic interaction at 4°C below the polymer's clouding temperature (CT), and the resulting complex demonstrated significantly improved salt and serum stability with increased hydrophobic interactions at temperatures (physiological condition, 37.5°C) above the CT. An in vitro study of the bioactivity of etanercept indicated that the TMN complex improves the long-term stability of etanercept in an aqueous environment because of the exposure of the functional active site and the molecular chaperone-like effect of the hydrophobic copolymer. This formulation possessed prolonged in vivo pharmacokinetic parameters. In a collagen-induced arthritis RA rat model, we verified the outstanding therapeutic effect of the TMN complexes. These results imply that this approach would be widely applied to protein and peptide delivery systems.
Temperature-modulated noncovalent interaction controllable (TMN) complex, the noncovalent interaction between polymer and therapeutic protein was enhanced by increasing temperature. The TMN complex showed significantly improved salt and serum stability at physiological temperature (37.5°C). [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23880471</pmid><doi>10.1016/j.jconrel.2013.07.012</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2013-10, Vol.171 (2), p.143-151 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1500772821 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | active sites animal models Animals Antirheumatic Agents - administration & dosage Antirheumatic Agents - chemistry Antirheumatic Agents - pharmacokinetics Arthritis, Experimental Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Bioavailability blood serum Cell Line, Tumor composite polymers Drug delivery Drug Delivery Systems electrolytes Electrostatic interactions Etanercept Female Glucans - chemistry hydrophobic bonding hydrophobicity Immunoglobulin G - administration & dosage Immunoglobulin G - chemistry in vitro studies Mice mixing Noncovalent interactions pharmacokinetics Polyesters - chemistry Rats Rats, Inbred Lew Receptors, Tumor Necrosis Factor - administration & dosage Receptors, Tumor Necrosis Factor - chemistry Rheumatoid arthritis Temperature therapeutics Tumor Necrosis Factor-alpha - metabolism |
title | Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A09%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temperature-modulated%20noncovalent%20interaction%20controllable%20complex%20for%20the%20long-term%20delivery%20of%20etanercept%20to%20treat%20rheumatoid%20arthritis&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Jung,%20Young-Seok&rft.date=2013-10-28&rft.volume=171&rft.issue=2&rft.spage=143&rft.epage=151&rft.pages=143-151&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.07.012&rft_dat=%3Cproquest_cross%3E1500772821%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-b53bb62bc77570b2040f5122f9d73d1cf07b2045b4df97e3e3897e3446ddea843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1431619259&rft_id=info:pmid/23880471&rfr_iscdi=true |